...Pulante is located in Xining in the Qinghai province of China and was founded in 2000. It develops, manufactures, markets, and distributes SFDA-approved Tibetan recipe-originated medicines in China. Pulante’s major revenue-generating product, Chongcao Qingfei Capsules, is an OTC product which alleviates the symptoms of respiratory diseases, and targets patients with Chronic Obstructive Pulmonary Disease ("COPD"), a common disease among more than 300 million smokers in China. In 2007, Pulante generated revenue of approximately RMB40 million and was profitable. Pulante’s manufacturing facility in Xining is a GMP-certified manufacturing facility.
Showing posts with label Qinghai Pulante Pharmaceutical. Show all posts
Showing posts with label Qinghai Pulante Pharmaceutical. Show all posts
Mar 21, 2008
Tongjitang to Enhance Product Portfolio with a Leading Pulmonary Disease Treatment in China
...Pulante is located in Xining in the Qinghai province of China and was founded in 2000. It develops, manufactures, markets, and distributes SFDA-approved Tibetan recipe-originated medicines in China. Pulante’s major revenue-generating product, Chongcao Qingfei Capsules, is an OTC product which alleviates the symptoms of respiratory diseases, and targets patients with Chronic Obstructive Pulmonary Disease ("COPD"), a common disease among more than 300 million smokers in China. In 2007, Pulante generated revenue of approximately RMB40 million and was profitable. Pulante’s manufacturing facility in Xining is a GMP-certified manufacturing facility.
Libellés :
Chronic Obstructive Pulmonary Disease (COPD),
Qinghai Pulante Pharmaceutical,
Tongjitang Chinese Medicines
Subscribe to:
Comments (Atom)